Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib as second-line maintenance in advanced colorectal cancer
ChiCTR2600122750Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in colorectal cancer (CRC), sponsored by Changzhou First People's Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600122750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122750.